European Journal of Endocrinology , 139 (5), 552561
The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs
coenzyme Q10, CoQ
Bien, nuestro requisito diettico de carnitina es cero
One of the key advantages of Ipamorelin is its minimal side effect profile
While these medications had impactful weight loss outcomes, with mean weight reduction in trials ranging from 7 to 10% [3,4,5], they lacked substantial evidence of improvement in cardiovascular outcomes